IP Verse

Use Of A Combination Comprising A Btk Inhibitor For Treating Cancers - EP3500299

The patent EP3500299 was granted to Beigene on Dec 13, 2023. The application was originally filed on Aug 18, 2017 under application number EP17841107A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3500299

BEIGENE
Application Number
EP17841107A
Filing Date
Aug 18, 2017
Status
Granted And Under Opposition
Nov 10, 2023
Grant Date
Dec 13, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KERNEBECK PATENTANWALTSSep 13, 2024KERNEBECKADMISSIBLE
TEVA PHARMACEUTICALSSep 12, 2024D YOUNGADMISSIBLE

Patent Citations (42) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2016CN95510
DESCRIPTIONWO2016CN96082
DESCRIPTIONUS4376110
DESCRIPTIONUS5811097
DESCRIPTIONUS5855887
DESCRIPTIONUS6051227
DESCRIPTIONUS6207157
DESCRIPTIONUS6682736
DESCRIPTIONUS6984720
DESCRIPTIONUS7488802
DESCRIPTIONUS7605238
DESCRIPTIONUS7943743
DESCRIPTIONUS8008449
DESCRIPTIONUS8168757
DESCRIPTIONUS8217149
DESCRIPTIONWO03042402
DESCRIPTIONWO2008156712
DESCRIPTIONWO2010036959
DESCRIPTIONWO2010089411
DESCRIPTIONWO2011066342
DESCRIPTIONWO2011082400
DESCRIPTIONWO2011159877
DESCRIPTIONWO2011161699
DESCRIPTIONWO2014173289
DESCRIPTIONWO2015035606
DESCRIPTIONWO2015061752
DESCRIPTIONWO2016087994
INTERNATIONAL-SEARCH-REPORTWO2014173289
INTERNATIONAL-SEARCH-REPORTWO2015061752
INTERNATIONAL-SEARCH-REPORTWO2016087994
INTERNATIONAL-SEARCH-REPORTWO2016100914
OPPOSITIONEP2989106
OPPOSITIONUS2015005277
OPPOSITIONWO2014173289
OPPOSITIONWO2015035606
OPPOSITIONWO2015061752
OPPOSITIONWO2016087994
OPPOSITIONWO2016100914
OPPOSITIONWO2016105582
OPPOSITIONWO2016128912
SEARCHWO2016100914
SEARCHWO2018193105

Non-Patent Literature (NPL) Citations (30) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Acerta Pharma Bv, "NCT02180711 | Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma", ClinicalTrials.gov, NLM, (20151116), pages 1 - 11, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02180711?cond=acalabrutinib%20non-hodgkin&rank=1&tab=history&a=4#version-content-panel, XP093216494
OPPOSITION- Acerta Pharma Bv, "NCT02362035 | ClinicalTrials.gov", ClinicalTrials.gov, NLM, (20160722), pages 1 - 11, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02362035?cond=NCT02362035%20&rank=1&tab=history&a=4#version-content-panel, XP093216495
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION. IMBRUVICA ® (ibrutinib) capsules, for oral use", HIGHLIGHTS OF PRESCRIBING INFORMATION. IMBRUVICA, FDA, (20160601), pages 1 - 32, HIGHLIGHTS OF PRESCRIBING INFORMATION. IMBRUVICA, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205552Orig1s012lbl.pdf, XP093216485
OPPOSITION- Beigene, "NCT02569476 | BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies ", ClinicalTrials.gov, NLM, (20160123), pages 1 - 12, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02569476?cond=NCT02569476%20&rank=1&tab=history&a=4#version-content-panel, XP093216490
OPPOSITION- Beigene, "NCT02795182 | Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGBA317) in Participants With B-cell Malignancies", ClinicalTrials.gov, NLM, (20160617), pages 1 - 12, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02795182?cond=NCT02795182&rank=1&tab=history&a=2#version-content-panel, XP093216488
OPPOSITION- Celgene Corporation, "NCT01744626 | Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ", ClinicalTrials.gov, NLM, (20160419), pages 1 - 16, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT01744626?cond=NCT01744626%20&rank=1&tab=history&a=17#version-content-panel, XP093216493
OPPOSITION- Clinicaltrials, "Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/ Refractory or Untreated CLL/SLL/PLL", National Libary of Medicine, NCT02296918, (20160202), pages 1 - 10, XP093227477
OPPOSITION- Clinicaltrials, "Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL (ElevateTN)", National Library of Medicine, NCT02475681, (20160808), pages 1 - 16, XP093227487
OPPOSITION- D38: International Nonproprietary Names (INN) programme entry 10553 for tislelizumab
OPPOSITION- D40: Shadman et al., (2024) Poster presented at 28th International Congress on Hematologic Malignancies
OPPOSITION- Hu Nan et al, "BTK inhibitor BCB-3111 synergizes with lenalidomide in MCL models", Cancer Res, Abstract 4796, (20160101), vol. 76, pages 1 - 4, XP093227516
OPPOSITION- Li Lucy, "BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317", BeiGene News, BeiGene, LTD., (20160629), pages 1 - 1, BeiGene News, URL: https://hkexir.beigene.com/news/beigene-announces-initiation-of-a-combination-trial-of-the-btk-inhibitor-bgb-3111-with-the-pd-1/f0673bb8-b61d-4645-9b5e-f098826143f4/, XP093216492
OPPOSITION- Li Na et al, "BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor FR", Cancer Res, Abstract 2597, (20150101), vol. 75, pages 1 - 4, XP093227507
OPPOSITION- N. Rajasekaran et al., "Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity", Bloodjournal.org Blood, 56th Annual Meeting of the American-Society-of-Hematology; San Francisco, CA, USA; December 06 -09, 2014, 56th Annual Meeting of the American-Society-of-Hematology; San Francisco, CA, USA; December 06 -09, 2014 , vol. 124, no. 21, (20141206), Bloodjournal.org Blood, URL: http://www.bloodjournal.org/content/124/21/3118, (20161110), XP002764065
OPPOSITION- Pohlmann Birgit-Kristin, "Innovation für Blutkrebs-Patienten", Deutsches Ärzteblatt, (20150227), pages 1 - 1, XP093227460
OPPOSITION- Raedler Lisa A, "Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström's Macroglobulinemia", American Health & Drug Benefits, (20160301), vol. 9, pages 89 - 92, XP093227459
OPPOSITION- Sun Zhijian , Dongping Zhou; Lusong Luo, " Effect of BTK inhibitors on differentiation of human monocyte-derived dendritic cells", Cancer Res, Abstract 5496, (20150101), vol. 75, pages 1 - 2, XP093227502
OPPOSITION- Maly Joseph, Blachly James S., "Author Manuscript: Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents", Current Hematologic Malignancy Reports, Springer US, New York, New York, (20160201), vol. 11, no. 1, doi:10.1007/s11899-016-0299-0, ISSN 1558-8211, pages 1 - 15, XP093216498
OPPOSITION- Al-Sawaf Othman et al, "Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial", Nature Medicine(Author manuscript ), Nature Publishing Group US, New York, New York, (20240101), vol. 30, no. 1, doi:10.1038/s41591-023-02722-9, ISSN 1078-8956, pages 240 - 248, XP093269118
OPPOSITION- Michael L. Wang et al, "Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma", The New England journal of medicine, Massachusetts Medical Society, US, US , (20130808), vol. 369, no. 6, doi:10.1056/NEJMoa1306220, ISSN 0028-4793, pages 507 - 516, XP055484912
OPPOSITION- John C. Byrd et al, "Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia", The New England journal of medicine, Massachusetts Medical Society, US, US , (20160128), vol. 374, no. 4, doi:10.1056/NEJMoa1509981, ISSN 0028-4793, pages 323 - 332, XP055471752
OPPOSITION- Zhang Qingyuan et al, "A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma", Leukemia & Lymphoma, Taylor & Francis, (20220824), vol. 63, no. 10, doi:10.1080/10428194.2022.2074985, ISSN 1042-8194, pages 2503 - 2506, XP093269121
OPPOSITION- A. Stathis, M. Ghielmini, "New agents for the treatment of lymphoma", Annals of Oncology, Kluwer Academic Publishers, (20120901), vol. 23, no. suppl 10, doi:10.1093/annonc/mds310, ISSN 09237534, pages x92 - x98, XP055056253
OPPOSITION- Na Li; Zhijian Sun; Ye Liu; Mingming Guo; Yilu Zhang; Dongping Zhou; Bo Zhang; Dan Su; Shuo Zhang; Jing Han; Yajuan Gao; Yunhang Guo; Zhiwei Wang; Min Wei; Lusong Luo; Lai Wang, "Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor | Cancer Research | American Association for Cancer Research", Cancer research, American Association for Cancer Research, San Diego, CA . Philadelphia (PA, San Diego, CA . Philadelphia (PA, (20150801), vol. 75, no. 15_Supplement, doi:10.1158/1538-7445.AM2015-2597, ISSN 0008-5472, pages 2597 - 2597, XP093216486
OPPOSITION- Rajasekaran Narendiran; Sadaram Mohith; Hebb Jonathan; Sagiv-Barfi Idit; Ambulkar Sid; Rajapaksa Amanda; Chang Serena; Chester Cariad; Waller Erin; Wang Lai; Lannutti Brian; Johnson Dave; Levy Ron; Kohrt Holbrook E, "Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity", Blood, American Society of Hematology, US, US , (20141114), vol. 124, no. 21, doi:10.1182/blood.V124.21.3118.3118, ISSN 0006-4971, page 3118, XP086744424
OPPOSITION- Tam Constantine et al, "The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial", Blood, issue 832, American Society of Hematology, US, US , (20151203), vol. 126, no. 23, doi:10.1182/blood.V126.23.832.832, ISSN 0006-4971, pages 1 - 5, XP086643906
OPPOSITION- Jingjing Wu, Mingzhi Zhang, Delong Liu, "Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor", Journal of Hematology & Oncology, (20161201), vol. 9, no. 1, doi:10.1186/s13045-016-0250-9, XP055359165
OPPOSITION- Wu Jingjing et al, "Second-generation inhibitors of Bruton tyrosine kinase", Journal of Hematology & Oncology, (20161201), vol. 9, no. 1, doi:10.1186/s13045-016-0313-y, XP093024482
OPPOSITION- Wu Jingjing, Liu Christina, Tsui Stella T., Liu Delong, "Second-generation inhibitors of Bruton tyrosine kinase", Journal of Hematology & Oncology, (20161201), vol. 9, no. 1, doi:10.1186/s13045-016-0313-y, XP093024482
OPPOSITION- Dreyling Martin et al, "A Phase III Study of Zanubrutinib Plus Rituximab Versus Bendamustine Plus Rituximab in Transplant-Ineligible, Untreated Mantle Cell Lymphoma", FUTURE ONCOLOGY, FUTURE MEDICINE LTD., LONDON, GB, GB , (20210101), vol. 17, no. 3, doi:10.2217/fon-2020-0794, ISSN 1479-6694, pages 255 - 262, XP093269125

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents